Parmax Pharma

Why is Parmax Pharma Ltd falling/rising?

As of 17-Jun, Parmax Pharma Ltd's stock price is rising, currently at 66.69, reflecting a 1.99% increase and a new 52-week high. The stock has gained 45.83% over the last eight days and significantly outperformed the Sensex, despite a decline in investor participation.

As of 17-Jun, Parmax Pharma Ltd's stock price is rising, currently at 66.69, which reflects a change of 1.3 or 1.99% increase. The stock has been on an upward trend, gaining for the last eight days and achieving a remarkable 45.83% return during this period. Additionally, it has reached a new 52-week high today. <BR><BR>The stock's performance over various time frames further illustrates its strength; it has increased by 113.96% over the past month and 97.13% year-to-date, significantly outperforming the Sensex, which has seen a decline of 9.46% in the same timeframe. Furthermore, Parmax Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 67.69% compared to the 5-day average. Despite this, the overall liquidity remains sufficient for trading. The combination of strong recent performance, reaching new highs, and consistent gains contributes to the stock's rising price.

Which are the latest news on Parmax Pharma?

What does Parmax Pharma do?

Parmax Pharma Ltd specializes in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO) within the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 3 Cr and a net profit of -1 Cr, with a market cap of INR 20 Cr.

Overview:<BR>Parmax Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry, focusing on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO).<BR><BR>History:<BR>Incorporated in November 1994, Parmax Pharma Ltd was promoted by Jayantilal S Dhol, Purushottam J Bhalodi, and Prabhudas D Hansalpara. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 3 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -2.36 <BR>Return on Equity: 85.92% <BR>Price to Book: -3.97 <BR><BR>Contact Details:<BR>Address: Plot No 20 Survey No 52, Tal Kotda Sangani Hadamtala Rajkot Gujarat : 360311 <BR>Tel: 91-2827-270534/535 <BR>Email: info@parmaxpharma.com <BR>Website: http://www.parmaxpharma.com

How big is Parmax Pharma?

As of 10th June, Parmax Pharma Ltd has a market capitalization of 20.00 Cr and reported Net Sales of 12.11 Cr with a Net Profit loss of 4.15 Cr over the latest four quarters.

As of 10th June, Parmax Pharma Ltd has a market capitalization of 20.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Parmax Pharma reported Net Sales of 12.11 Cr. However, the company experienced a Net Profit loss of 4.15 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds stood at a loss of 1.99 Cr, while Total Assets were valued at 18.56 Cr.

Who are in the management team of Parmax Pharma?

The management team of Parmax Pharma includes Umang Alkesh Gosalia as Managing Director, Pramay Amritlal Chhatra and Ami R Shah as Non-Executive & Independent Directors, and Yash Vora as Company Secretary & Compliance Officer.

The management team of Parmax Pharma includes the following individuals:<BR><BR>1. Umang Alkesh Gosalia - Managing Director<BR>2. Pramay Amritlal Chhatra - Non-Executive & Independent Director<BR>3. Ami R Shah - Non-Executive & Independent Director<BR>4. Yash Vora - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Parmax Pharma?

Parmax Pharma's peers include Ishita Drugs, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Starsource Multi, Zenith Health, Ortin Global, Colinz Labs, and Mono Pharmacare. Cian Healthcare leads with a 1-year return of 100%, while Parmax Pharma has a return of 48.68%.

Peers: The peers of Parmax Pharma are Ishita Drugs, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Starsource Multi, Zenith Health, Ortin Global, Colinz Labs, and Mono Pharmacare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ishita Drugs, Desh Rakshak, Parmax Pharma, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, Colinz Labs, and Mono Pharmacare, while Starsource Multi does not qualify. Growth is excellent at Dipna Pharmachem, while below average growth is found at Ishita Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, and the rest. Good capital structure is noted at Dipna Pharmachem, Zenith Health, and Colinz Labs, while below average capital structure is seen at Ishita Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Ortin Global, Mono Pharmacare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Cian Healthcare at 100.00%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Parmax Pharma's own 1-year return is 48.68%, which is significantly higher than Dipna Pharmachem's but lower than Cian Healthcare's. Additionally, peers with negative six-month returns include Dipna Pharmachem and Zenith Health.

Should I buy, sell or hold Parmax Pharma Ltd?

When is the next results date for Parmax Pharma Ltd?

The next results date for Parmax Pharma Ltd is June 2, 2026.

The next results date for Parmax Pharma Ltd is scheduled for June 2, 2026.

Are Parmax Pharma Ltd latest results good or bad?

Parmax Pharma Ltd's latest results are concerning, showing a net loss of ₹0.73 crores in Q3 FY26, a significant decline in revenue by 72.74% year-on-year, and a negative operating margin of -62.85%. The company is facing serious financial challenges, indicating a bleak outlook for investors.

Parmax Pharma Ltd's latest results are concerning and indicate significant operational distress. The company reported a net loss of ₹0.73 crores in Q3 FY26, which is an alarming 87.20% decline quarter-on-quarter. Revenue also plummeted by 72.74% year-on-year to just ₹2.53 crores, reflecting a severe drop from ₹9.28 crores in the same quarter last year.<BR><BR>The operating margin has turned negative at -62.85%, a drastic fall from a positive margin of 2.16% a year ago, indicating that the company is struggling to maintain profitability. Additionally, the negative book value of ₹-4.47 per share raises serious concerns about the company's financial health and solvency.<BR><BR>Overall, these results suggest that Parmax Pharma is facing significant challenges, and the outlook appears bleak, with six consecutive quarters of losses and a deteriorating balance sheet. Investors should approach this situation with caution, as the company requires substantial restructuring and capital infusion to stabilize its operations.

How has been the historical performance of Parmax Pharma?

Parmax Pharma has experienced fluctuating financial performance, with net sales increasing from 11.05 Cr in Mar'24 to 28.20 Cr in Mar'25, but facing ongoing profitability challenges, including negative profits after tax of -2.09 Cr in Mar'25 and deteriorating reserves of -6.44 Cr. Despite revenue growth, the company struggles with liquidity and a rising debt burden.

Answer:<BR>The historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Parmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriorating financial position. Total assets increased to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, while total liabilities also rose to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, indicating a growing debt burden. Cash flow from operating activities remained stagnant at 0.00 Cr in Mar'24 and Mar'23, highlighting liquidity issues. Overall, while there are signs of revenue growth, Parmax Pharma continues to face significant profitability and financial stability challenges.

Who are the top shareholders of the Parmax Pharma?

The top shareholders of Parmax Pharma are Alkesh Mahasukh Gopani with 17.92%, and Gosalia Meena Alkesh with 12.69%. Individual investors hold a combined 63.1%, with no institutional holdings or pledged shares reported.

The top shareholders of Parmax Pharma include Alkesh Mahasukh Gopani, who holds the highest promoter stake at 17.92%. The highest public shareholder is Gosalia Meena Alkesh, with a holding of 12.69%. Additionally, individual investors collectively own 63.1% of the company. There are no institutional holdings or pledged promoter shares reported.

Is Parmax Pharma overvalued or undervalued?

As of February 1, 2024, Parmax Pharma's valuation has downgraded to risky, with negative financial ratios indicating it is overvalued compared to peers like Cipla and Dr. Reddy's, and its stock has underperformed with a year-to-date return of -10.06%.

As of 1 February 2024, the valuation grade for Parmax Pharma has moved from attractive to risky, indicating a significant downgrade in its perceived value. The company is currently assessed as overvalued, with a PE ratio of -14.03, an EV to EBIT of -21.92, and a Price to Book Value of -7.19. These ratios suggest that the company is struggling financially, as reflected in its negative return on capital employed (ROCE) of -13.70% and negative return on equity (ROE).<BR><BR>In comparison to its peers, Parmax Pharma stands out negatively against companies like Cipla Ltd., which has a PE ratio of 22.99 and an EV to EBITDA of 15.93, and Dr. Reddy's Laboratories Ltd., with a PE of 19.49 and an EV to EBITDA of 12.87. The stark contrast in valuation metrics underscores the challenges Parmax Pharma faces within the pharmaceuticals and biotechnology industry. Additionally, the company's recent stock performance has been disappointing, with a year-to-date return of -10.06%, significantly lagging behind the Sensex's 5.58% return.

What is the technical trend for Parmax Pharma?

As of June 3, 2025, Parmax Pharma's technical trend is mildly bullish, supported by daily moving averages and monthly Bollinger Bands, despite some caution from weekly MACD and Dow Theory indicators.

As of 3 June 2025, the technical trend for Parmax Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, primarily driven by the daily moving averages indicating mild bullishness, while the monthly Bollinger Bands show a mildly bullish trend. However, the weekly MACD and Dow Theory are both mildly bearish, indicating some caution. The KST remains bullish on both weekly and monthly time frames, providing some support to the overall mildly bullish outlook. The RSI shows no signals in both weekly and monthly time frames, suggesting a lack of momentum. Overall, while there are mixed signals, the prevailing trend is mildly bullish.

Has Parmax Pharma declared dividend?

No Dividend History Available